European Journal of Rheumatology
Case Report

Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis

1.

Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey

2.

Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey

3.

Department of Medical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey

Eur J Rheumatol 2018; 5: 75-78
DOI: 10.5152/eurjrheum.2016.15081
Read: 1323 Downloads: 778 Published: 03 September 2019

Abstract

 

The use of anti-tumor necrosis factor alpha (anti-TNF-α) agents has increased during the past decade in rheumatology practice. Opportunistic infections have been reported with anti-TNF-α agents in clinical trials and post-marketing usage. Aspergillus infection is a rare opportunistic infection that is associated with immunosuppression, and there are reported cases of pulmonary aspergillosis in various rheumatic diseases treated with anti-TNF-α agents. Here, we present the first case of pulmonary aspergillosis associated with infliximab treatment in a patient with Still’s disease.

 

Cite this article as: Şeyhoğlu E, Erden A, Kılıç L, Karadağ Ö, Arıkan Akdağlı S, Akdoğan A, et al. Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis. Eur J Rheumatol 2018; 5: 75-8.

Files
EISSN 2148-4279